ERAS
Erasca, Inc.
Biotechnology · Healthcare · United States
14.35
close · 2026-10-30
value
93
cheaper than peers93
quality
41
stronger fundamentals41
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | -2.1% | 95 |
| earnings yield, latest year | -3.1% | 94 |
| cash flow yield, 2 years ago | -2.5% | 86 |
| earnings yield, 1 year ago | -4.8% | 85 |
| earnings yield, 2 years ago | -5.8% | 85 |
| cash flow yield, 1 year ago | -2.6% | 84 |
| cash flow yield, 3 years ago | -2.4% | 82 |
| earnings yield, 3 years ago | -13.9% | 70 |
| price to book | 12.39× | 12 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| return on equity | -69.9% | 49 |
| debt to equity | 11.7% | 40 |
3 of 4 measures available
Facts
| market cap | $5B |
| free cash flow | -$212.7M |
| employees | 103 |
| first trade | 2021-07-16 |
| next earnings | not reported |
| fundamentals updated | 2026-07-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.44 | -0.69 | -0.83 | -1.99 |
| free cash flow | -$105.1M | -$132.0M | -$123.0M | -$119.8M |
| net income | -$124.5M | -$161.7M | -$125.0M | -$242.8M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | -$9.5M | -$22.5M | $0 | -$102.0M |